Document is current
Any future updates will be listed below
-
Authors
Guzeloglu-Kayisli, Ozlem https://orcid.org/0000-0001-5448-917X
Ozmen, Asli https://orcid.org/0000-0002-2024-6249
Un, Busra Cetinkaya https://orcid.org/0000-0001-9466-4278
Un, Burak https://orcid.org/0000-0002-8885-7062
Blas, Jacqueline
Johnson, Isabella
Thurman, Andrea
Walters, Mark
Friend, David
Kayisli, Umit A https://orcid.org/0000-0002-0379-2168
Lockwood, Charles J
-
Funding
Funding for this research was provided by:
HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R41 HD113465-01)
HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R41 HD113465-01)
- License Information
-
More Information
Article History
Received: 21 December 2024
Revised: 23 February 2025
Accepted: 24 February 2025
First Online: 17 March 2025
Disclosure and competing interests statement
: Ozlem Guzeloglu-Kayisli, Umit A Kayisli, and Charles J Lockwood are inventors on patent application that includes use of 15dPGJ2 in preventing preterm birth. sabella Johnson is the Senior Manager of Product Development at Dare Bioscience, Andrea Thurman is a Medical Director of Dare Bioscience, Mark Walters is a co-founder and serves as the Vice President of Operations at Dare Bioscience, and David Friend is the Chief Scientific Officer of Dare Bioscience. The authors declare no competing interests.
